Loading
Acute Heart Failure / Ketone Ester (KetoneAid MonoEster) · Interventional Study
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for a planned interventional trial comparing ketone ester supplementation to placebo in patients hospitalized with acute heart failure. No results are reported; the study has not yet begun recruitment. The trial is designed to measure change in NT-proBNP as the primary endpoint over 5 days or until discharge.
Interventional, Randomized, Sequential, Quadruple masking, Treatment purpose. Acute Heart Failure; age from 18 Years. Intervention: KetoneAid MonoEster. Compared with: Placebo — Placebo Comparator. n = 60. 1 site: Canada.
This is a registry record for a planned interventional trial comparing ketone ester supplementation to placebo in patients hospitalized with acute heart failure. No results are reported; the study has not yet begun recruitment. The trial is designed to measure change in NT-proBNP as the primary endpoint over 5 days or until discharge.
Secondary endpoints (KCCQ scores, echocardiographic hemodynamics) and exploratory clinical outcomes (mortality, ICU admission) are listed but outcome data are not available.
The source did not state who this applies to in practice.
This is a planned interventional trial with no results posted; it is early-phase work designed to assess acute effects of a novel therapy in a serious condition.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07434466). This is a study registration, not published results. Lead sponsor: University of Alberta. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Acute Heart Failure. Interventions: DIETARY_SUPPLEMENT: Ketone Ester (KetoneAid MonoEster); DIETARY_SUPPLEMENT: Placebo. Primary outcome measures: Change in NT-proBNP , Baseline to Day 5 (or hospital discharge if earlier). Brief summary: Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.